Study of CT1390B for relapsed or refractory acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment, CT1390B, for people whose acute myeloid leukemia (AML) has come back or not responded to other treatments. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a type of AML that is positive for a marker called CLL-1.
- Your leukemia cells in the bone marrow must be at least 5%.
- You should be in generally good health, with a heart function above 50% and normal liver and kidney function.
- You cannot have had certain previous treatments, like CAR-T therapy or a stem cell transplant in the last 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CT0991 for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It focuses on patients whose cancer cells show a high level of a protein called CD38.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
This trial is testing an investigational cell therapy called CT1195E for people with certain types of B-cell lymphoma or acute lymphoblastic leukemia that has come back or stopped responding to treatment. The goal is to see if CT1195E can help control the cancer.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This trial tests a new type of immune cell therapy (CAR-T) that targets three proteins (CLL1, CD33, NKG2D) on leukemia cells in patients with acute myeloid leukemia that has not responded to or come back after prior treatment.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.